Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9869052 | 0.84 | BACE1 (0.43) | BACE1PTPN1GLANPSR1ALDH1A1 | |
| SCHEMBL9533254 | 0.82 | BACE1 (0.42) | BACE1GLANPSR1ALDH1A1 | |
| SCHEMBL7436519 | 0.81 | BACE1 (0.41) | BACE1GLANPSR1ALDH1A1 | |
| SCHEMBL10530016 | 0.81 | BACE1 (0.35) | BACE1 | |
| SCHEMBL4459751 | 0.81 | BACE1 (0.46) | BACE1PTPN1GLANPSR1ALDH1A1 | |
| SCHEMBL31603 | 0.77 | BACE1 (0.44) | BACE1PTPN1GLANPSR1ALDH1A1 | |
| SCHEMBL5924541 | 0.77 | BACE1 (0.33) | BACE1ALDH1A1 | |
| SCHEMBL587175 | 0.77 | ALDH1A1 (0.46) | BACE1GLANPSR1ALDH1A1 | |
| SCHEMBL24309470 | 0.76 | BACE1 (0.42) | BACE1PTPN1GLANPSR1 | |
| SCHEMBL1403061 | 0.76 | BACE1 (0.42) | BACE1PTPN1GLANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778188-A | Preparation method of alternaria tenuifolia keto acid and derivatives thereof | 安徽农业大学 | 2021-05-11 | — | — | CN | claimed |
| EP-0194906-B1 | HETEROCYCLIC DISSYMMETRIC 1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC-ACID ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE | FOURNIER INNOVATION ET SYNERGIE (FR) | 1989-07-19 | — | — | EP | claimed |
| EP-0194906-A2 | Heterocyclic dissymmetric 1,4-dihydropyridine-3,5-dicarboxylic-acid esters, process for their preparation and their therapeutical use | FOURNIER INNOVATION ET SYNERGIE (FR) | 1986-09-17 | — | — | EP | claimed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| CN-113402436-B | Tertiary amino acid derivative, preparation method and application thereof | 安徽农业大学 | 2024-07-12 | — | — | CN | disclosed |
| CN-116425684-A | Synthesis method of oxaagole sodium intermediate | 安徽联创生物医药股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-04-06 | — | — | US | disclosed |
| CN-113582904-B | 5-n-propyl-4-hydroxypyrrole-2-ketone derivative and preparation method and application thereof | 安徽农业大学 | 2023-03-10 | — | — | CN | disclosed |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-03-09 | — | — | US | disclosed |
| EP-0194906-B1 | HETEROCYCLIC DISSYMMETRIC 1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC-ACID ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE | FOURNIER INNOVATION ET SYNERGIE (FR) | 1989-07-19 | — | — | EP | disclosed |
| US-4710505-A | VASODILATORS, HYPOTENSIVES | SOCIETE DE RECHERCHES INDUSTRIELLES (S.O.R.I.) (FR) | 1987-12-01 | — | — | US | disclosed |
| US-4686217-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS | FISONS PLC (GB) | 1987-08-11 | — | — | US | disclosed |
| EP-0225175-A2 | Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof | FISONS plc (GB) | 1987-06-10 | — | — | EP | disclosed |
| EP-0194906-A2 | Heterocyclic dissymmetric 1,4-dihydropyridine-3,5-dicarboxylic-acid esters, process for their preparation and their therapeutical use | FOURNIER INNOVATION ET SYNERGIE (FR) | 1986-09-17 | — | — | EP | disclosed |
| US-4607041-A | CARDIOTONIC AGENTS | FISONS PLC (GB) | 1986-08-19 | — | — | US | disclosed |
| EP-0174131-A2 | Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them | FISONS plc (GB) | 1986-03-12 | — | — | EP | disclosed |
| EP-0145434-A2 | Novel dihydropyridine derivatives and process for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-06-19 | — | — | EP | disclosed |
| EP-0125803-A2 | Pharmaceutically active dihydropyridines | FISONS plc (GB) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, NQO1, VKORC1 | BACE1 4499/4885PTPN1 3886/4885GLA 760/4885 |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, VKORC1, PANK3 | BACE1 4463/4885PTPN1 2952/4885GLA 900/4885 |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VNN1, VKORC1, PANK3 | BACE1 4463/4885PTPN1 2952/4885GLA 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.